BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

846 related articles for article (PubMed ID: 19273710)

  • 61. Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients.
    Paiella S; Malleo G; Cataldo I; Gasparini C; De Pastena M; De Marchi G; Marchegiani G; Rusev B; Scarpa A; Girelli R; Giardino A; Frigerio I; D'Onofrio M; Secchettin E; Bassi C; Salvia R
    Langenbecks Arch Surg; 2018 Mar; 403(2):213-220. PubMed ID: 28983662
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
    Witkiewicz AK; McMillan EA; Balaji U; Baek G; Lin WC; Mansour J; Mollaee M; Wagner KU; Koduru P; Yopp A; Choti MA; Yeo CJ; McCue P; White MA; Knudsen ES
    Nat Commun; 2015 Apr; 6():6744. PubMed ID: 25855536
    [TBL] [Abstract][Full Text] [Related]  

  • 63. MicroRNA 483-3p suppresses the expression of DPC4/Smad4 in pancreatic cancer.
    Hao J; Zhang S; Zhou Y; Hu X; Shao C
    FEBS Lett; 2011 Jan; 585(1):207-13. PubMed ID: 21112326
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Biological identification of ampullary adenocarcinomas.
    Relias V; Saif MW
    JOP; 2014 Jul; 15(4):306-7. PubMed ID: 25076327
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
    McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
    Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
    Sun H; Zhang B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
    [TBL] [Abstract][Full Text] [Related]  

  • 67. KRAS in pancreatic cancer.
    Agarwal A; Saif MW
    JOP; 2014 Jul; 15(4):303-5. PubMed ID: 25076326
    [TBL] [Abstract][Full Text] [Related]  

  • 68. DPC4 gene expression in primary pancreatic ductal adenocarcinoma: relationship with CT characteristics.
    Choi SH; Kim HJ; Kim KW; An S; Hong SM; Kim SC; Kim MH
    Br J Radiol; 2017 May; 90(1073):20160403. PubMed ID: 28339284
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
    Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
    Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Optimizing methods for the diagnosis of pancreatic cancer.
    Brugge WR
    J Clin Gastroenterol; 2007; 41(10):869-70. PubMed ID: 18090153
    [No Abstract]   [Full Text] [Related]  

  • 72. Neuroendocrine carcinoma of the pancreas with similar genetic alterations to invasive ductal adenocarcinoma.
    Kimura T; Miyamoto H; Fukuya A; Kitamura S; Okamoto K; Kimura M; Muguruma N; Ikemoto T; Shimada M; Yoneda A; Bando Y; Takishita M; Takayama T
    Clin J Gastroenterol; 2016 Aug; 9(4):261-5. PubMed ID: 27262570
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Translational research in pancreatic cancer: KRAS and beyond.
    Boeck S; Ormanns S; Haas M; Bächmann S; Laubender RP; Siveke JT; Jung A; Kirchner T; Heinemann V
    Pancreas; 2014 Jan; 43(1):150-2. PubMed ID: 24326376
    [No Abstract]   [Full Text] [Related]  

  • 74. Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass.
    Maluf-Filho F; Kumar A; Gerhardt R; Kubrusly M; Sakai P; Hondo F; Matuguma SE; Artifon E; Monteiro da Cunha JE; César Machado MC; Ishioka S; Forero E
    J Clin Gastroenterol; 2007; 41(10):906-10. PubMed ID: 18090159
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Genetic diagnosis of human pancreatic cancer].
    Horii A
    Nihon Shokakibyo Gakkai Zasshi; 2003 Mar; 100(3):292-7. PubMed ID: 12696169
    [No Abstract]   [Full Text] [Related]  

  • 76. Tracking the Clonal Evolution of Adenosquamous Carcinoma, a Rare Variant of Intraductal Papillary Mucinous Neoplasm of the Pancreas.
    Matsuzaka S; Karasaki H; Ono Y; Ogata M; Oikawa K; Tamakawa S; Chiba S; Muraki M; Yokochi T; Funakoshi H; Kono T; Nagashima K; Mizukami Y
    Pancreas; 2016 Jul; 45(6):915-8. PubMed ID: 27295533
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.
    Moore PS; Sipos B; Orlandini S; Sorio C; Real FX; Lemoine NR; Gress T; Bassi C; Klöppel G; Kalthoff H; Ungefroren H; Löhr M; Scarpa A
    Virchows Arch; 2001 Dec; 439(6):798-802. PubMed ID: 11787853
    [TBL] [Abstract][Full Text] [Related]  

  • 78. KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin.
    Shi C; Hong SM; Lim P; Kamiyama H; Khan M; Anders RA; Goggins M; Hruban RH; Eshleman JR
    Mol Cancer Res; 2009 Feb; 7(2):230-6. PubMed ID: 19208745
    [TBL] [Abstract][Full Text] [Related]  

  • 79. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
    Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
    J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
    Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
    J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.